that contain or consist of viable cells or tissues that have been modified to alter the biological characteristics of those cells or tissues or that are intended to be used in the transfer of the therapeutic gene. Ensure that your product is intended for therapeutic use rather than research purposes.

2. **Somatic Cell Therapy Medicinal Products**: These products manipulate cells for therapeutic purposes to treat, prevent, or diagnose diseases. It is vital to document the source of these cells and ensure compliance with regulatory standards regarding their origin and quality.

3. **Tissue-engineered Products**: These utilize human tissues or cells. A key consideration includes whether the product will be used for repairing or replacing human tissues. Clear product definitions and intended uses help in establishing a sound classification strategy.

Moreover, borderline products with mixed composition may arise. These are products that may not clearly fall into ATMP definitions. In such cases, understanding the nuances of HCT/P 361 vs. 351 in the U.S. regulatory context becomes essential, as classification can heavily influence regulatory approach and market authorization pathways.

Step 2: Engaging in Pre-submission Scientific Advice Meetings

The second step involves actively engaging with regulatory agencies, specifically through Scientific Advice meetings offered by EMA’s Committee for Advanced Therapies (CAT). These meetings provide an essential platform to obtain guidance on product development, addressing early-stage questions about classification, testing strategies, and compliance with Good Manufacturing Practice (GMP) guidelines.

To prepare for a Scientific Advice meeting, follow these practical actions:

• Identify Key Questions: List specific queries related to ATMP classification, including but not limited to, safety assessments and manufacturing processes.
• Gather Preliminary Data: Compile initial scientific data, risk assessments, quality information, and any preclinical or clinical evidence you may have.
• Draft the Meeting Pack: The meeting pack should clearly outline the product, the rationale for its classification, and the specific questions for which advice is sought. Ensure the document is formatted according to EMA guidelines (available on the <a href="https://www.ema.europa.eu/enEMA website).
• Consult Regulatory Experts: It is advisable to collaborate with EMA ATMP regulatory consulting experts who can provide insights into the nuances of the classification process and help craft an effective submission.

Once your meeting pack is submitted, expect to receive detailed feedback during the meeting, which will provide a clearer regulatory pathway for your ATMP. This interaction can significantly influence your development strategy and assist in refining your project based on expert guidance.

Step 3: Documenting Development and Regulatory Pathway

Following the Scientific Advice meeting, a critical phase occurs: the documentation of development activities and the implementation of favorable regulatory strategies. This process must be meticulously curated to align with ICH-GCP and EMA directives, considering the expectations for preclinical and clinical data submissions.

1. **Regulatory Pathway Planning**: Develop a detailed regulatory strategy document outlining the approved advice from EMA and subsequent action items that will guide your product towards market authorization. Include timelines, key milestones, and responsible stakeholders.

2. **Preclinical Studies**: Outline the necessary preclinical studies required to demonstrate product safety and efficacy. Ensure alignment with the guidelines suggested during the Scientific Advice meeting. The documentation should cover:

• Design of preclinical studies.
• Compliance with ethical standards of animal welfare and ICH guidelines.
• Detailed methodologies to be employed and endpoints to be assessed.

3. **Clinical Development Plan**: Your clinical development plan should reflect advice received about trial design, patient selection criteria, endpoints of efficacy, and safety assessments. Here are some key aspects to document:

• Phases of clinical trials (I, II, III).
• Monitoring and reporting plans that meet regulatory expectations.
• Strategies for navigating potential challenges with borderline products.

Collectively, these documents should provide a cohesive picture of your ATMP’s journey through the development and submission phases—a critical factor for successful regulatory submissions and obtaining clinical trial authorization within the EU framework.

Step 4: Submitting the Marketing Authorization Application (MAA)

Once the necessary data has been accumulated, the focus shifts towards compiling the Marketing Authorization Application (MAA). The application is a comprehensive document that lays out your product’s scientific and regulatory justification, substantiated by robust evidence and adherence to regulatory frameworks.

1. **Compilation of the MAA**: Your MAA should be structured according to the Common Technical Document (CTD) format. Key sections to include are:

• Module 1 – Administrative Information: This section contains the cover letter, product information, and administrative details.
• Module 2 – Summaries: Summarize the key quality, safety, and efficacy data presented in subsequent modules. This is an opportunity to emphasize critical findings stemming from scientific advice.
• Modules 3, 4, and 5 – Quality, Safety, and Efficacy Data: Include comprehensive data reflecting the Quality (C1), Nonclinical (C4), and Clinical (C5) findings along with planned clinical trials and associated data.

2. **Quality Assurance (QA) Checks**: Implement QA checks prior to submission. Internal compliance reviews help in identifying data gaps or inconsistencies that can hinder the regulatory approval process.

3. **Engagement with Regulatory Agencies**: After submission of the MAA, be prepared for correspondences with regulatory agencies. EMA may request additional information, clarification, or even conduct inspections of the manufacturing facilities. Maintaining effective communication establishes your commitment to compliance and willingness to adapt based on feedback.

Step 5: Navigating the Review Process

The review process is a critical phase in the MAA journey. It involves regulatory authorities, scientific experts, and an assessment of your submitted dossier by the EMA’s CAT. Understanding this process will enhance your readiness to respond to queries and streamline approval timelines.

1. **Assessment Phases**: The EMA follows a systematic review procedure. Initial reception involves acceptance checks of the MAA, followed by a detailed examination of the data provided in the application. Expect the 210-day review process to consist of:

• **Day 0-70**: Validation of application submission and preliminary assessment of the dossier for completeness.
• **Day 70-150**: Evaluations of the quality, efficacy, and safety data conducted by the committee.
• **Day 150-210**: Final assessment includes drafting a report and preparing for opinion and decision-making discussions.

2. **Post-Submission Clarifications**: During the review process, the EMA may issue requests for additional information. Timely responses to these requests are essential to prevent extensions of the evaluation timeframe and potential delays in marketing authorization.

3. **Expert Meetings**: You may also consider engaging with expert meetings if specific concerns regarding your submission arise. Thorough preparation and a clear understanding of the data presented can significantly bolster your case.

Step 6: Post-Approval Commitments and Continuous Compliance

After successful approval of the marketing authorization, the final step is ensuring ongoing compliance with regulatory commitments and managing post-approval obligations. Understanding these can help in sustaining market authorization and monitoring product safety.

1. **Risk Management Plans (RMPs)**: Develop risk management strategies as instructed by the EMA. RMPs are necessary to monitor long-term safety of ATMP products. Regular updates and compliance with the RMP should be ensured throughout the product lifecycle.

2. **Periodic Safety Update Reports (PSURs)**: Prepare to generate and submit PSURs detailing ongoing assessments of risk-benefit profiles of the product. These reports should reflect the latest safety data and clinical experiences learned in the real-world use of the product.

3. **Engagement in Post-Marketing Studies**: Commit to conducting post-marketing studies or surveillance as required by the EMA. This engagement helps ensure that real-world data supports ongoing safety and efficacy.

4. **Continued Dialogue with Regulatory Authorities**: Maintain communication lines with the EMA and adapt to any further requirements or changes in regulatory expectations post-approval. Ensuring compliance with current guidelines established by the EMA and other regulatory bodies is paramount for the sustainability of your ATMP in the market.

In conclusion, the journey through ATMP classification and regulatory submissions is intricate and requires strategic planning, clear documentation, and continuous engagement with regulatory entities. Implementing this step-by-step guide in your Scientific Advice strategy will lead your ATMP towards successful classification, paving the way for transformative therapeutic products to reach patients effectively.